Gene News and Research

Latest Gene News and Research

Modified spider-silk proteins for nonviral gene delivery

Genetically engineered spider silk could help overcome a major barrier to the use of gene therapy in everyday medicine, according to a new study that reported development and successful initial laboratory tests of such a material. It appears in ACS' journal Bioconjugate Chemistry.

11 Aug 2011

Gene therapy to combat leukemia

In a medical breakthrough scientists have found that gene therapy could be used to cure leukemia. Researchers at the University of Pennsylvania engineered patients' own pathogen-fighting T-cells to target a molecule found on the surface of leukemia cells. These genetically modified T-cells were grown outside of the body and infused back into patients suffering from late-stage chronic lymphocytic leukemia (CLL), which affects the blood and bone marrow and is the most common form of leukemia.

11 Aug 2011

Bristol-Myers Squibb, GNS collaborate to identify biomarkers in immuno-inflammation

GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced that it has entered into a collaboration with Bristol-Myers Squibb Company focused on the discovery of novel disease biology and biomarkers in the area of immuno-inflammation.

11 Aug 2011

Gastroenterology journal publishes results of Lexicon LX1031 Phase 2 trial in IBS

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that results from the Phase 2 clinical trial of LX1031 in patients with non-constipating irritable bowel syndrome (IBS) were published earlier this week in the August 2011 edition of the journal Gastroenterology.

11 Aug 2011

Abbott launches new molecular assay to detect vector-borne microorganisms

Abbott's Ibis Biosciences today introduced a new molecular assay to detect a wide variety of vector-borne microorganisms, including those known to cause Lyme Disease, Rocky Mountain Spotted Fever, Babesiosis, Ehrlichiosis and Anaplasmosis.

11 Aug 2011

Cancer-causing fusion protein works by silencing tumor suppressor gene IL-2Rγ

Mariusz A. Wasik, MD, professor of Pathology and Laboratory Medicine, and Qian Zhang, MD, PhD, research assistant professor, both from the Perelman School of Medicine at the University of Pennsylvania, and their colleagues, found that a cancer-causing fusion protein works by silencing the tumor suppressor gene IL-2R common gamma-chain.

10 Aug 2011

Scientist determines how nyctalopin gene makes night vision possible

A scientist from the Florida campus of The Scripps Research Institute has determined how a particular gene makes night vision possible. The study, which was published in the August 10, 2011 edition of The Journal of Neuroscience, focuses on a gene called nyctalopin. Mutations in the gene result in inherited "night blindness," a loss of vision in low-light environments.

10 Aug 2011

Noninvasive prenatal DNA test can detect fetus at risk for sex-linked disorders

As a noninvasive method of determining the sex of a fetus, tests using cell-free fetal DNA obtained from the mother's blood after 7 weeks gestation performed well, while urine-based tests appear to be unreliable, according to a review and analysis of previous studies, reported in the August 10 issue of JAMA.

10 Aug 2011

New genetic cause of retinitis pigmentosa

Combining the expertise of several different labs, University of Iowa researchers have found a new genetic cause of the blinding eye disease retinitis pigmentosa (RP) and, in the process, discovered an entirely new version of the message that codes for the affected protein.

10 Aug 2011

NanoString launches nCounter Rat miRNA Expression Assay Kit

NanoString Technologies, Inc., a privately held provider of life science tools for translational research and developer of molecular diagnostics, today announced the availability of the nCounter Rat miRNA Expression Assay Kit for use on its nCounter Analysis System.

From NanoString Technologies 9 Aug 2011

Positive data from Lexicon LX1032 Phase 2 study on carcinoid syndrome

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced positive, top-line proof-of-concept data from its recently completed Phase 2 study in carcinoid syndrome with LX1032, telotristat etiprate. Carcinoid syndrome is a chronic condition caused by neuroendocrine tumors that usually originate from the gastrointestinal tract.

9 Aug 2011

Researchers clarify role of two proteins key to T-cell development

In the latest issue of Nature, researchers at the Perelman School of Medicine at the University of Pennsylvania clarify the role of two proteins key to T-cell development.

9 Aug 2011

Lentiviral vector can kill HIV-infected cells

In what represents an important step toward curing HIV, a USC scientist has created a virus that hunts down HIV-infected cells.

9 Aug 2011

Criterium to manage Senesco's SNS01-T Phase Ib/2a multiple myeloma study

Senesco Technologies, Inc. today announced that it has contracted Criterium, Inc. to manage the operational aspects of its Phase Ib/2a clinical study of SNS01-T, the Company's lead therapeutic candidate for the treatment of multiple myeloma.

9 Aug 2011

Lexicon's second quarter revenues decrease 55% to $0.6 million

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three and six months ended June 30, 2011.

9 Aug 2011

Genetically altered spermless ‘mozzies’ to combat malaria

In a fresh new attempt to combat malaria, researchers have developed another way to reduce the numbers of the malaria-spreading blood-suckers: introduce genetically altered spermless males into the population.

8 Aug 2011

HUYA enters strategic partnership with King's Lab

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovations, today announced a strategic partnership with the Shanghai Jiao Tong University School of Pharmacy King's Lab. The alliance with HUYA will assist King's Lab in accelerating the development of their novel drugs to international standards.

8 Aug 2011

Response Genetics second quarter total revenue increases 18.8% to $6.7 million

Response Genetics Inc., a company focused on the development and sale of molecular diagnostic tests for cancer, today announced its consolidated financial results and business progress for the second quarter ended June 30, 2011.

8 Aug 2011

Researchers discover gene variant linked to meningiomas

The causes of brain tumours have been hard to discern in most cases. But Umeå researchers have previously identified an inherited predisposition for brain tumours, and now, in an international collaboration, they have also discovered a genetic variation that increases the risk of a certain type of brain tumour, called meningiomas.

8 Aug 2011

Affymetrix announces commercialization of next-generation human transcriptome array

Affymetrix, Inc. today announced commercialization of the next-generation human transcriptome array demonstrated by Stanford University researchers to be superior to mRNA sequencing (RNA-Seq) in gene expression profiling studies.

8 Aug 2011